Your browser is no longer supported. Please, upgrade your browser.
Settings
ARDM Aradigm Corporation daily Stock Chart
ARDM [NASD]
Aradigm Corporation
Index- P/E- EPS (ttm)-1.93 Insider Own2.50% Shs Outstand13.75M Perf Week16.00%
Market Cap19.94M Forward P/E- EPS next Y-0.38 Insider Trans-1.08% Shs Float8.58M Perf Month-4.61%
Income-28.50M PEG- EPS next Q-0.30 Inst Own38.80% Short Float0.56% Perf Quarter4.32%
Sales1.90M P/S10.49 EPS this Y-91.00% Inst Trans-1.03% Short Ratio0.79 Perf Half Y-18.54%
Book/sh-0.52 P/B- EPS next Y65.50% ROA-100.80% Target Price7.50 Perf Year-69.15%
Cash/sh1.25 P/C1.16 EPS next 5Y- ROE-664.50% 52W Range0.78 - 7.19 Perf YTD-9.37%
Dividend- P/FCF- EPS past 5Y-1.90% ROI-211.40% 52W High-79.83% Beta1.19
Dividend %- Quick Ratio1.50 Sales past 5Y-24.40% Gross Margin- 52W Low85.90% ATR0.14
Employees23 Current Ratio1.50 Sales Q/Q28116.70% Oper. Margin- RSI (14)56.09 Volatility16.75% 9.97%
OptionableNo Debt/Eq- EPS Q/Q54.60% Profit Margin- Rel Volume1.18 Prev Close1.34
ShortableYes LT Debt/Eq- EarningsAug 14 BMO Payout- Avg Volume61.06K Price1.45
Recom1.00 SMA207.30% SMA5010.12% SMA200-40.86% Volume71,958 Change8.21%
May-15-17 07:06AM  Aradigm reports 1Q loss Associated Press
07:00AM  Aradigm Announces First Quarter 2017 Financial Results Business Wire
Mar-30-17 05:05PM  ARADIGM CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
Mar-28-17 07:14AM  Aradigm reports 4Q loss Associated Press
07:00AM  Aradigm Announces Fourth Quarter 2016 and Full Year Financial Results Business Wire
Feb-09-17 07:00AM  Aradigm to Present at the Biotechnology Industry Organization (BIO) CEO & Investor Conference 2017 on February 13 Business Wire +6.77%
Jan-06-17 07:00AM  Aradigm to Present at 9th Annual Biotech Showcase Conference on January 9 Business Wire +6.06%
Dec-16-16 07:58PM  pSivida Corp. (PSDV): Heres How It Stacks Up Versus Its Peers at Insider Monkey -7.14%
Dec-02-16 05:02PM  ARADIGM CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits -5.24%
04:29PM  Aradigm Lung Infection Antibiotic Fails Trial (ARDM) Investopedia
04:29PM  Aradigm Lung Infection Antibiotic Fails Trial (ARDM) at Investopedia
01:23PM  Dont Write Off Aradigm Corporation (ARDM) Just Yet Insider Monkey
01:23PM  Dont Write Off Aradigm Corporation (ARDM) Just Yet at Insider Monkey
Dec-01-16 11:56AM  Aradigm Shares Plunge After Releasing Mixed Clinical Trial Results For Pulmaquin TheStreet.com -56.30%
11:56AM  Aradigm Shares Plunge After Releasing Mixed Clinical Trial Results For Pulmaquin at TheStreet
08:41AM  Aradigm Corp. drops 54% in pre-market trade on results of two late-stage clinical trials at MarketWatch
07:47AM  Aradigm posts mixed late-stage data on inhaled antibiotic Reuters
07:00AM  Aradigm Announces Top-Line Results from Two Phase 3 Studies Evaluating Pulmaquin for the Chronic Treatment of Non-Cystic Fibrosis Bronchiectasis Patients with Lung Infections with Pseudomonas aeruginosa Business Wire
Nov-18-16 01:04PM  ARADIGM CORP Financials
Nov-10-16 04:42PM  ARADIGM CORP Files SEC form 10-Q, Quarterly Report
11:20AM  Aradigm Corp. :ARDM-US: Earnings Analysis: Q3, 2016 By the Numbers : November 10, 2016 Capital Cube
11:20AM  Aradigm Corp. :ARDM-US: Earnings Analysis: Q3, 2016 By the Numbers : November 10, 2016
07:00AM  Aradigm to Present at the Stifel 2016 Healthcare Conference on November 16 Business Wire
Nov-09-16 05:25PM  ARADIGM CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits -5.57%
07:08AM  Aradigm reports 3Q loss
07:00AM  Aradigm Announces Third Quarter 2016 Financial Results Business Wire
Oct-18-16 07:00AM  Multi-million Dollar DTRA Funding for Biodefense Research with Aradigms Inhaled Ciprofloxacin Business Wire
Oct-07-16 07:00AM  Aradigm Announces Australian Research Council Funding to Develop Nanotechnologies Targeting Bacterial and Fungal Biofilms Business Wire
Sep-22-16 09:11AM  3 Reasons Why Aradigm Corporation (ARDM) is a Great Momentum Stock +19.96%
07:00AM  Aradigm Announces Last Patient Dosing Visit in ORBIT-3 and ORBIT-4 Phase 3 Studies of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis Patients Business Wire
Sep-21-16 07:00AM  Aradigm to Host Analyst Meeting and Webcast on September 26 in New York City Business Wire
05:49AM  Aradigm (ARDM) Shares March Higher, Can It Continue?
Sep-20-16 07:00AM  Aradigm to Present at the Ladenburg Thalmann 2016 Healthcare Conference on September 27 Business Wire
Aug-12-16 11:23AM  Aradigm Corp. :ARDM-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016
Aug-11-16 07:04AM  ARADIGM CORP Files SEC form 10-Q, Quarterly Report
Aug-10-16 05:17PM  ARADIGM CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
07:05AM  Aradigm reports 2Q loss
07:00AM  Aradigm Announces Second Quarter 2016 Financial Results Business Wire
Jun-10-16 05:02PM  ARADIGM CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
May-24-16 01:49PM  The Sub Dollar Stock In The 800 Billion Cigarette Industry The Tobacco Giants Need To Stay Relevant -6.88%
May-17-16 12:15PM  Aradigm Corp. :ARDM-US: Earnings Analysis: Q1, 2016 By the Numbers
May-11-16 07:00AM  Two Presentations on Aradigms Inhaled Liposomal Ciprofloxacin Programs at the American Thoracic Society 2016 International Conference Business Wire
May-10-16 05:45PM  ARADIGM CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
05:45PM  ARADIGM CORP Files SEC form 10-Q, Quarterly Report
09:03AM  Aradigm reports 1Q loss
07:00AM  Aradigm Announces First Quarter 2016 Financial Results Business Wire
Apr-29-16 09:42AM  Activist Starboard Value Gets Seats on Marvell Technology Group Ltd. (MRVL)s Board; Two Other Hedge Funds Disclose Latest Moves at Insider Monkey
Apr-28-16 04:08PM  ARADIGM CORP Files SEC form 8-K/A, Financial Statements and Exhibits EDGAR Online -7.02%
Apr-27-16 04:30PM  ARADIGM CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligatio EDGAR Online
Apr-26-16 07:00AM  Aradigm Corporation Announces First Closing of Private Placement Offering of $23 Million Senior Convertible Notes Due 2021 Business Wire
Apr-25-16 12:08PM  ARADIGM CORP Files SEC form 8-K, Financial Statements and Exhibits EDGAR Online
Apr-22-16 08:15AM  Aradigm Corporation Prices Private Placement of Senior Notes Business Wire +7.69%
Mar-30-16 02:33PM  ARADIGM CORP Files SEC form 10-K, Annual Report
Mar-17-16 07:00AM  Aradigm Announces Decision for Centralized Review of Pulmaquin by the European Medicines Agency Business Wire
Mar-16-16 07:02AM  ARADIGM CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits +7.24%
Mar-15-16 07:13AM  Aradigm reports 4Q loss +9.01%
07:00AM  Aradigm Announces Fourth Quarter 2015 and Full Year Financial Results Business Wire
Feb-02-16 07:00AM  Aradigm to Present at the Biotechnology Industry Organization (BIO) CEO & Investor Conference 2016 on February 8 Business Wire -6.56%
Jan-05-16 07:00AM  Aradigm to Host Corporate Update Conference Call on January 6 Business Wire
Dec-23-15 05:16PM  Aradigm Corp.: Sudden move in price, will it continue? -5.01%
Dec-21-15 12:11PM  Aradigm Corp. Earnings Analysis: Q3, 2015 By the Numbers
Dec-03-15 08:40AM  How it All Plays Out - Research on Aradigm, Ideal Power, CareDx, and Colony Bankcorp Accesswire
Nov-12-15 03:20PM  ARADIGM CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
06:12AM  ARADIGM CORP Files SEC form 10-Q, Quarterly Report
Nov-11-15 07:06AM  Aradigm reports 3Q loss
07:00AM  Aradigm Announces Third Quarter 2015 Financial Results Business Wire
Oct-30-15 03:19PM  Aradigm Corp. Value Analysis (NASDAQ:ARDM) : October 30, 2015
Oct-13-15 07:00AM  Aradigm Corporation Completes Enrollment in the Second Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis (ORBIT-3) Business Wire -8.57%
Sep-23-15 07:00AM  Aradigm to Present at the Ladenburg Thalmann 2015 Healthcare Conference on September 29 Business Wire
Sep-22-15 07:00AM  Aradigm Corporation Completes Enrollment in Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis (ORBIT-4) Business Wire
Sep-10-15 07:00AM  Results from Pulmonary Non-Tuberculous Mycobacteria (PNTM) Study Using Aradigm's Liposomal Ciprofloxacin to Be Presented at ICAAC/ICC 2015 Business Wire
Sep-04-15 04:10PM  ARADIGM CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Principal Officer
Aug-15-15 08:10PM  10-Q for Aradigm Corp. at Company Spotlight
Aug-14-15 10:02AM  ARADIGM CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
Aug-13-15 06:24PM  ARADIGM CORP Files SEC form 10-Q, Quarterly Report
07:15AM  Aradigm reports 2Q loss
07:00AM  Aradigm Announces Second Quarter 2015 Financial Results Business Wire
Jun-10-15 09:29AM  Aradigm (ARDM) is Overbought: Is A Drop Coming? - Tale of the Tape
09:21AM  Aradigm Corporation (ARDM) in Focus: Stock Jumps 5.5% - Tale of the Tape
May-18-15 05:17PM  ARADIGM CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
May-14-15 04:39PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of ARADIGM CORPORATION Business Wire
May-13-15 08:11PM  10-Q for Aradigm Corp. at Company Spotlight
May-12-15 07:00AM  Results from Pulmonary Non-Tuberculous Mycobacteria (PNTM) Study Using Aradigms Liposomal Ciprofloxacin to be Presented at the American Thoracic Society 2015 International Conference Business Wire
May-11-15 05:29PM  ARADIGM CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
07:09AM  Aradigm reports 1Q loss
07:00AM  Aradigm Announces First Quarter 2015 Financial Results Business Wire
May-03-15 08:13PM  10-K for Aradigm Corp. at Company Spotlight
Apr-21-15 07:26AM  Aradigm Announces Appointment of Dr. Robert A. Reed as Vice President, Regulatory (Chemistry, Manufacturing and Controls) and Quality at noodls
07:00AM  Aradigm Announces Appointment of Dr. Robert A. Reed as Vice President, Regulatory (Chemistry, Manufacturing and Controls) and Quality Business Wire
Apr-16-15 07:00AM  Aradigm to Host Key Opinion Leader Breakfast and Webcast on April 23 in New York City Business Wire
Mar-20-15 02:32PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of Aradigm Corporation -- ARDM PR Newswire
Mar-18-15 06:07AM  ARADIGM CORP Files SEC form 10-K, Annual Report
Mar-17-15 04:04PM  ARADIGM CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
07:23AM  Aradigm Announces Fourth Quarter 2014 and Full Year Financial Results at noodls
07:22AM  Aradigm reports 4Q loss
07:00AM  Aradigm Announces Fourth Quarter 2014 and Full Year Financial Results Business Wire
Feb-27-15 07:29AM  Aradigm Corporation President & CEO Dr. Igor Gonda, Ph.D. to Be Interviewed Live on iHeart Radio/ Clear Channel Atlanta Studios - 640 WGST AM's "Health Tech Talk Live" at noodls
07:15AM  Aradigm Corporation President & CEO Dr. Igor Gonda, Ph.D. to Be Interviewed Live on iHeart Radio/ Clear Channel Atlanta Studios - 640 WGST AM's "Health Tech Talk Live" Marketwired
Feb-04-15 07:00AM  Aradigm to Present at the Biotechnology Industry Organization (BIO) CEO & Investor Conference 2015 on February 10 Business Wire
Jan-14-15 07:00AM  Aradigm Granted Key Composition of Matter Patents for Pulmaquin in Europe and Australia Business Wire
Aradigm Corporation, a specialty pharmaceutical company, focuses on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases. The company's lead development candidates are proprietary formulations of the potent antibiotic ciprofloxacin, including Linhaliq (ARD-3150) and Lipoquin (ARD-3100) that are delivered by inhalation for the management of infections associated with severe respiratory diseases, including non-cystic fibrosis bronchiectasis and cystic fibrosis. It is also developing inhaled ciprofloxacin formulations for treatment of patients with cystic fibrosis and non-tuberculous mycobacteria, as well as the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, melioidosis, Q fever, and inhaled anthrax. The company has collaboration agreements with Oregon State University and Grifols, S.A. Aradigm Corporation was founded in 1991 and is headquartered in Hayward, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Froehlich Juergen KurtChief Medical OfficerApr 04Sale1.513,7655,68585,129Apr 06 01:06 PM
Froehlich Juergen KurtChief Medical OfficerOct 04Sale6.764232,85988,894Oct 05 04:31 PM